SORT1 and frontotemporal dementia: In fact, the biotech company Alector is testing an anti-SORT1 antibody in phase 3 clinical trials for the treatment of FTD, and is recruiting patients to evaluate the efficacy of the anti-SORT1 antibody (ClinicalTrials.gov, 2020).